We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+31.01%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$570M
AUM Growth
+$85.9M
Cap. Flow
-$10.1M
Cap. Flow %
-1.78%
Top 10 Hldgs %
79.11%
Holding
57
New
1
Increased
2
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$46.1M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$2.79M
3
CYPH
Cypherpunk Technologies Inc
CYPH
+$2.6M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$13.4M
2
ACLX
Arcellx
ACLX
+$11.3M
3
VRNA
Verona Pharma
VRNA
+$7.41M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$6.52M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$5.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.66%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INZY
51
DELISTED
Inozyme Pharma
INZY
– –
-504,407
Closed -$2.89M
KALA icon
52
KALA BIO
KALA
$14.5M
– –
-240
Closed -$181K
SRZN icon
53
Surrozen
SRZN
$297M
– –
-20,000
Closed -$181K
ATYR
54
aTyr Pharma
ATYR
$50.1M
– –
-1,750,000
Closed -$3.67M
NGM
55
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-13,669
Closed -$55.8K
BCEL
56
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-262,827
Closed -$300K
AMYT
57
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
– –
-304,715
Closed -$4.44M
1 2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q2 2023 Portfolio in Review

As of Q2 2023, Samsara BioCapital held 57 positions worth $570M, up 18% from $484M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Samsara BioCapital's Q2 2023 filing shows 1 new, 2 increased, 9 reduced and 10 closed positions. Its largest new stake was ACELYRIN: 2,256,022 shares worth $47.2M. The largest sale was IVERIC bio, Inc. Common Stock, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Samsara BioCapital's largest Q2 2023 buy was ACELYRIN: 2,256,022 shares worth $47.2M.
  • Samsara BioCapital added most to LYRA THERAPEUTICS INC in Q2 2023, an estimated $2.79M increase.
  • Samsara BioCapital's biggest Q2 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $13.4M.
  • Samsara BioCapital fully exited Centessa Pharmaceuticals in Q2 2023, selling an estimated $6.52M.
  • Samsara BioCapital's ten largest holdings make up 79% of its $570M portfolio in Q2 2023.
  • Samsara BioCapital opened 1 new position and closed 10 in Q2 2023.
  • Samsara BioCapital's portfolio value rose 18% quarter-over-quarter to $570M.

Based on Samsara BioCapital's 13F filing for Q2 2023, filed 14 Aug 2023.